|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01858 CHUNLI MEDICAL
Nominal 
8.780 -0.190 (-2.118%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 805,857 | -33.319% | 1,208,524 | 1,201,604 | 1,108,140 | 937,686 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (28,529) | 85.112% | (15,412) | (20,777) | (27,290) | (6,224) | |
| Profit / (Loss) on Disposal | 39 | 904.293% | 4 | 25 | 15 | (158) | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 131,599 | -56.981% | 305,906 | 336,880 | 367,379 | 329,847 | |
| Taxation | (6,938) | -75.299% | (28,088) | (29,161) | (45,018) | (46,473) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 327 | 5439.946% | 6 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 124,988 | -55.012% | 277,824 | 307,719 | 322,361 | 283,373 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (17,068) | 2.930% | (16,582) | (20,175) | (9,642) | (1,637) |
| Depreciation & Amortisation | 37,677 | 8.719% | 34,655 | 30,162 | 18,526 | 15,166 |
| Directors' Emoluments | 2,842 | -27.820% | 3,938 | 3,780 | 3,444 | 3,758 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 33.000 | -54.167% | 72.000 | 80.000 | 93.000 | 82.000 |
| DPS (cts) | 13.200 | -- | 36.200 | 31.300 | 13.000 | 0.000 |
| Dividend Payout Ratio (%) | 40.000% | -- | 50.278% | 39.125% | 13.978% | -- |
| Cash flow per share ($) | (0.005) | -- | 1.334 | 0.107 | 0.476 | 0.754 |
| NBV per share ($) | 7.368 | -- | 7.502 | 7.077 | 6.425 | 3.122 |
| Remarks: | Real time quote last updated: 16/04/2025 17:22 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 124,988,010 |
| %Change | -55.012% |
| EPS / (LPS) | RMB 0.330 |
| NBV Per Share (¥) | RMB 7.368 |